Name Address/P.O. Box Postal Code/City Country
›
› › ›
CO.DON AG Warthestr. 21 (Headquarters) 14513 Teltow Germany
›
Subsidiary: Deutscher Platz 5d 04103 Leipzig Germany Matthias Meißner, M.A. (Director Corporate Communications / IR / PR) +49-341-99190-330 +49-341-99190-309 info@codon.de www.codon.de 150 (2021) 1993 GMP/Integrated Isolator Technology (IIT)
Areas of Activity
›
Tissue Engineering
Biological Patents
›
Address/P.O. Box Postal Code/City Country Contact Person
Telephone Fax Email Website Number of Employees Founded (year) Type of Laboratory
External Collaborations
Request for Further Collaborations
› › › ›
› › › › › ›
›
›
For cell-based human tissue engineering therapeutics Various ongoing projects with several well-renowned hospitals, universities, and university hospitals in Europe in the field of product distribution, product development, clinical evaluation, and research CO.DON AG is seeking national and international corporate partners who have substantial resources in the field of tissue engineering and regeneration for distribution and marketing of the company’s products (international) as well as for the development of product lines.
The Company CO.DON AG develops, produces and markets autologous cell therapies for the minimally invasive repair of knee cartilage defects following trauma or degeneration. The medicinal product is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). CO.DON’s method is currently used in over 200 clinics in Germany and more than 17,000 patients have already been treated. In July 2017 CO.DON received EU-wide marketing authorisation for its product, with approval for Switzerland following in March 2019. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: ISIN DE000A3E5C08). Executive Board: Tilmann Bur. CO.DON AG manufactures cell-based therapies of the highest purity and to the highest quality standards. Its products represent a revolutionary process in the biological regenerative treatment of articular cartilage defects. The products are 100% autologous and free of additives, setting the stage for the highest level of personalized treatment. Because no exogenous materials are used, the risks of rejection, inflammation, and infection are low. Due to a minimally invasive or arthroscopic application of the product, surgery and rehabilitation time can be reduced. CO.DON AG is certified in accordance with European Guidelines for Good Manufacturing Practice (EU-GMP) since 1997. In 1997 CO.DON AG was the first bio pharmaceutical company in Europe to be granted a permit for the manufacture of autologous chondrocyte transplants under section 13 of the German Drugs Law (AMG).
